This site is intended for healthcare professionals
EMC Drug Feed
Drug information

Cymex CreamOwn Label Supplier:Superdrug Lip & Cold Sore CreamLip and Cold Sore Relief Cream

OTC
Read time: 2 mins
Last updated: 20 Feb 2018
...
 

Summary of product characteristics


1. Name of the medicinal product

Cymex CreamOwn Label Supplier:Superdrug Lip & Cold Sore CreamLip and Cold Sore Relief Cream


2. Qualitative and quantitative composition

Urea PhEur

1.0% w/w

Cetrimide PhEur

0.5% w/w

Dimeticone 350 PhEur

9.0% w/w

Chlorocresol PhEur

0.1% w/w

For a full list of excipients, see section 6.1.


3. Pharmaceutical form

Emollient White Cream


4.1. Therapeutic indications

For the application to cold sores and cracked lips.


4.2. Posology and method of administration

There are no special hazards associated with the use of cetrimide in specific patient groups. No special precautions or modified dosage requirements are, therefore, indicated for its use in infants, the elderly or during pregnancy or lactation. No hazardous drug interactions are considered likely.Adults, elderly and children: apply sparingly every hour for the relief of cold sores and cracked lips.Topical application.


4.3. Contraindications

Hypersensitivity to urea, cetrimide, dimeticone, chlorocresol or to any of the excipients listed in section 6.1.


4.4. Special warnings and precautions for use

Cymex Cream contains cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis). Keep out of the sight and reach of children. For external use only. If symptoms persist consult your doctor.


4.5. Interaction with other medicinal products and other forms of interaction

None known.


4.6. Fertility, pregnancy and lactation

Consult a doctor before use if pregnant or breast-feeding.


4.7. Effects on ability to drive and use machines

Not applicable.


4.8. Undesirable effects

None.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; website: www.mhra.gov.uk/yellowcard


4.9. Overdose

FeaturesSymptoms are unlikely to arise after ingestion of this product. It is possible that nausea and vomiting or diarrhoea may occur.ManagementGut decontamination or other specific management is unlikely to be required. Treat symptomatically. A small glass of milk or water may be helpful.


5.1. Pharmacodynamic properties

ATC Code DO 2A X Urea has keratolytic properties, Cetrimide is a quaternary ammonium disinfectant, Chlorocresol is a mild disinfectant while Dimeticone 350 acts as a water repellent.


5.2. Pharmacokinetic properties

Not applicable.


5.3. Preclinical safety data

No particular remarks.


6.1. List of excipients

Deionised Water Liquid paraffin BP Cetosteryl Alcohol BP


6.2. Incompatibilities

Not applicable.


6.3. Shelf life

36 months


6.4. Special precautions for storage

Store below 25°C.


6.5. Nature and contents of container

5 g White Aluminium tubes with Elongated nozzles and HDPE caps. Internally lacquered.


6.6. Special precautions for disposal and other handling

See 4.2 Posology and Method of Administration.


7. Marketing authorisation holder

Actavis Group PTC ehfReykjavíkurvegi 76-78220 HafnarfjordurIceland.Own label supplier:Superdrug Stores plcAdmail 838CroydonSurreyCR9 4WZEnglandOwn label supplier:Boots the Chemist plc1 Thane RoadNottinghamNG2 3AAEngland


8. Marketing authorisation number(s)

PL 30306/0028


9. Date of first authorisation/renewal of the authorisation

13th December 2007


10. Date of revision of the text

24.08.2015

4.1 Therapeutic indications

For the application to cold sores and cracked lips.

4.2 Posology and method of administration

There are no special hazards associated with the use of cetrimide in specific patient groups. No special precautions or modified dosage requirements are, therefore, indicated for its use in infants, the elderly or during pregnancy or lactation. No hazardous drug interactions are considered likely.Adults, elderly and children: apply sparingly every hour for the relief of cold sores and cracked lips.Topical application.

4.3 Contraindications

Hypersensitivity to urea, cetrimide, dimeticone, chlorocresol or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Cymex Cream contains cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis). Keep out of the sight and reach of children. For external use only. If symptoms persist consult your doctor.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

Consult a doctor before use if pregnant or breast-feeding.

4.7 Effects on ability to drive and use machines

Not applicable.

4.8 Undesirable effects

None.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; website: www.mhra.gov.uk/yellowcard

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).